The Daily Toke

March 30, 2026

# THC & POLITICS: Army Opens Doors, States Chase Revenue, Public Health Warnings Mount

The U.S. Army is making a historic shift in recruitment policy, now allowing enlistees with a single marijuana possession conviction to join without a waiver—a move effective April 20th that signals the military's pivot toward workforce flexibility in an era of widespread cannabis legalization. Meanwhile, Congress is churning: sixteen cannabis bills filed in the current session include the MORE Act (which would federally deschedule cannabis entirely and has 62 sponsors—more than any other cannabis proposal), the STATES 2.0 Act (allowing interstate commerce between legal jurisdictions), and the CLIMB Act (enabling state-legal marijuana businesses to list on major stock exchanges like Nasdaq). 💰 MONEY MOVES These legislative pushes arrive as the U.S. legal cannabis market is projected to reach $30.5 billion in 2026, up 4.9% from last year—bouncing back from what Whitney Economics says was the first annual revenue decline in the history of regulated markets. The 2025 downturn came largely from supply saturation and pricing compression, but New York and Ohio's expanded retail access prevented the damage from being worse.

At the state level, the cannabis revenue chase is accelerating. Pennsylvania Gov. Josh Shapiro's 2026-27 budget projects $729 million in new tax revenue if recreational marijuana is legalized—but the legislature remains split on whether a new Cannabis Control Board or the state Liquor Control Board should oversee regulation. Republican Sen. Dan Laughlin (Erie County) backs the new board; Democratic Rep. Dan Frankel (Pittsburgh) favors the LCB's proven track record managing alcohol sales. 💰 MONEY MOVES Frankel said he's open to discussion: "I never say never." Georgia lawmakers voted 144-21 to approve the "Putting Georgia's Patients First Act," which would remove THC potency caps for medical patients, allow vaping, and expand qualifying conditions—moving the state closer to becoming the 41st state with a comprehensive medical marijuana program. Mississippi passed two bills awaiting the governor's signature that remove potency caps on cannabis oils and eliminate required follow-up doctor appointments. Delaware approved medical cannabis use in hospitals for terminally ill patients. Yet Mississippi voters rejected most of the thirty-plus expansion bills filed this session, including all recreational legalization attempts, signaling mixed political appetite even in states with existing programs.

Public health professionals are raising alarms about legalization's unintended consequences. A licensed psychologist and attorney at Massachusetts General Hospital wrote in The Boston Globe that Massachusetts has followed a "predictable arc" of rapid commercialization and normalization, with cannabis-related psychiatric disorders among youth increasing sharply after legalization—even as young people increasingly view the drug as low-risk. The pattern mirrors alcohol's history: prohibition incentivizes higher-potency products (spirits over beer), a shift that persisted after repeal. Cannabis is now repeating this pattern, with legalization expanding access to products far more potent than pre-prohibition street cannabis. Rep. Kathy Rapp (R-Warren County, Pennsylvania) cited a JAMA study showing 10-30% of regular users develop cannabis use disorder with symptoms including low mood, anxiety, and apathy—concerns she argues outweigh any tax revenue. Yet the public health debate remains lopsided. 🤔 THINK ABOUT IT Alcohol kills approximately 95,000 Americans annually and prescription opioids kill over 16,000—cannabis has zero recorded overdose deaths in human history. So which substances warrant the tighter regulatory frameworks?

Massachusetts voters legalized recreational cannabis in 2016, but a 2026 ballot campaign called the Coalition for a Healthy Massachusetts is pushing a question to repeal legalization, citing odor complaints, impaired driving risks, and insufficient long-term safety data. Campaign spokeswoman Wendy Wakeman told lawmakers that "Massachusetts is just not as comfortable a place to live in anymore," pointing to cannabis ubiquity on public transit and highways. Yet when confronted with the ballot question's own black-market risks—it would allow any adult to possess and gift an ounce of cannabis regardless of licensing—Wakeman acknowledged the concern was "a great question." Rep. Michael Day seized on the contradiction: "So are we not setting up a black market with this question?" The proposal would maintain medical dispensaries but eliminate retail stores, a structure that mirrors early alcohol prohibition enforcement failures.

[THIS] Federal attention is shifting toward mental health applications and veteran support. Utah Gov. Spencer Cox (R) signed a bill funding clinical trials on psychedelic-assisted therapy for military veterans with serious mental health conditions. Hawaii's House Health Committee unanimously approved a Senate-passed bill creating a Mental Health Emerging Therapies Task Force to study psilocybin and MDMA access—the FDA has already designated both as breakthrough therapies. Delaware, Washington, and New Mexico are advancing similar psychedelics legislation. 🚀 THIS IS COOL The federal recognition of breakthrough therapy status for psilocybin and MDMA represents a significant shift in how psychiatry views plant medicines for trauma and treatment-resistant depression. Yet progress remains inconsistent: President Trump recently signed a law to recriminalize hemp THC products, which could undermine Medicare's new pilot program launching April 1st that covers up to 3 milligrams of hemp-derived THC for Medicare patients. The Centers for Medicare & Medicaid Services confirmed the coverage details, but the program's timeline is now uncertain if federal restrictions take effect.

Ohio voters overwhelmingly approved a cannabis legalization measure in 2023, but the state legislature has since quietly rewritten the law in ways that subverted the original voter mandate—a pattern that raises questions about democratic legitimacy when legislatures override direct democracy on drug policy. Meanwhile, a federal bill warned of by House Judiciary Committee Ranking Member Jamie Raskin (D-Maryland) would allow non-citizens gathered to smoke marijuana—even legally in their state—to be designated a "criminal gang" and deported without a hearing. 🤔 THINK ABOUT IT The contradiction is stark: the Army recruits cannabis users, states race to tax cannabis sales, veterans demand access to cannabis and psychedelics for PTSD, yet federal law still treats cannabis possession as grounds for deportation and gang designation. The market is normalizing. Policy is fragmenting. And public health institutions are warning that speed matters—legalization's commercial arc is already written, and the moment to center youth protection is narrowing.

March 30, 2026

Texas hemp retailers are facing a March 31 deadline that could eliminate 60-70% of their inventory and force widespread business closures across what industry leaders describe as an $8 billion sector. The Texas Department of State Health Services has adopted new regulations that redefine how THC is measured—shifting from a Delta-9 THC standard to a "Total THC" calculation that includes THCA, a compound that converts to intoxicating THC when heated. Smokable THCA flower, pre-rolled joints, and hemp buds will effectively disappear from shelves, with retailers conducting fire sales over the weekend to clear stock before the rules take effect. 💰 MONEY MOVES The financial hit extends beyond lost sales: manufacturer licenses will jump from $258 to $10,000 annually, while retail registration fees spike from $155 to $5,000—a change one Austin retailer called "a pretty terrifying number to encounter as a small business." With roughly 1,500 hemp shops across Texas occupying millions of square feet in strip centers and high-traffic retail corridors, the regulatory overhaul threatens immediate closures and industry-wide layoffs.

The legal challenge has already begun. Boomtown Vapor LLC filed a lawsuit in Travis County on March 17, arguing that the Texas Department of State Health Services is overstepping its authority by unilaterally redefining the legal standard for hemp without legislative action. The lawsuit challenges both the "Total THC" standard and the $5,000 registration fee as a "prohibitive tax" designed to destroy the industry rather than regulate it. A judge has yet to rule on the requested temporary restraining order, but the timeline is razor-thin—the new rules are set to become fully enforceable on April 1. This legal battle echoes last year's near-miss, when the Texas Legislature passed a hemp-ban bill that Governor Greg Abbott vetoed in June 2025, calling it legally flawed. Instead of an outright ban, Abbott issued Executive Order GA-56 in September, directing state agencies to implement new hemp-related rules—the regulations now facing court challenge.

🤔 THINK ABOUT IT Edibles and beverages will remain legal under the new regime, offering a potential lifeline for some retailers, but shops built around higher-margin smokable products may not survive the pivot. The Texas Hemp Business Council warns that the changes are "hugely consequential to the industry," with Mark Bordas, the council's executive director, stating that "you're going to be wiping out access to a lot of product in a very short period of time." Meanwhile, the federal horizon presents an even larger existential threat: a provision in the federal spending bill would ban the sale of most hemp-derived THC products beginning November 12, capping THC at 0.4 milligrams per container—a deadline that industry experts describe as an "existential threat" to the entire sector unless Congress acts. Rep. James Baird introduced H.R. 7010 to push the federal ban deadline to November 2028, while a bipartisan HEMP Act would authorize FDA regulation rather than outright prohibition.

Pennsylvania district attorneys are also pushing for hemp regulation, though their focus is narrower. In a letter to Governor Josh Shapiro and state lawmakers, the Pennsylvania District Attorneys Association outlined a "wish list" of legislative changes that includes regulation of intoxicating hemp products sold in smoke shops. The requests signal a pattern: states and localities are tightening oversight of hemp-derived THC products, but through different mechanisms—some through outright bans, others through fee-based licensing and product restrictions. The industry is watching closely to see whether court intervention in Texas slows the regulatory wave or whether other states follow suit with similar rules before the federal deadline in November.

March 30, 2026

# THC in Science: Mental Health Claims Collapse, Medicare Wades In, and Driving Questions Persist

Federal health officials are moving forward with Medicare coverage for hemp-derived CBD products starting April 1, 2026, even as the largest clinical review of medical cannabis to date delivers a devastating verdict on its mental health applications. The Centers for Medicare & Medicaid Services announced that participating healthcare organizations can furnish up to $500 annually in CBD products to Medicare beneficiaries at no cost to patients, with products capped at 3 milligrams of total THC per serving. The pilot covers three CMS Innovation Center models and requires third-party testing for potency and contaminants. 💰 MONEY MOVES This represents the first federal insurance coverage for cannabis products, though the initiative faces complications: President Trump recently signed legislation to recriminalize hemp THC products, which could affect the program's scope before it even launches. Medicare would not reimburse participating organizations—they absorb the costs themselves—meaning this is less a healthcare mandate than a voluntary program that pushes financial responsibility onto providers.

The timing is awkward because major new research directly contradicts the mental health claims driving much of cannabis's popularity. A massive meta-analysis published in The Lancet Psychiatry examining 54 clinical trials spanning 1980 to 2025 found no strong evidence that cannabinoid-based treatments work for anxiety, depression, or PTSD. Dr. Jack Wilson from the University of Sydney's Matilda Centre, the lead author, noted that cannabis may actually carry risks, including a greater likelihood of developing psychosis or delaying more effective treatment for existing mental health disorders. This finding contradicts what many Americans believe: roughly 20% of U.S. adults already use CBD products, and a significant percentage report using cannabis specifically to treat mood and anxiety disorders. The research suggests that patients may be experiencing temporary symptom masking rather than actual therapeutic benefit—a distinction with real consequences for long-term mental health outcomes. 🤔 THINK ABOUT IT If cannabis doesn't treat anxiety or depression but people feel temporarily better, are we helping patients heal or just delaying them from getting real treatment?

Where cannabis does show promise is narrower but more solid. 🚀 THIS IS COOL A new study in the Journal of Pain Research found that full-spectrum CBD-dominant extracts significantly outperformed synthetic THC (dronabinol) in older adults with chronic pain. Analyzing data from 968 German patients aged 65 and older, researchers found that 85.7% of those using CBD-dominant extracts met the primary outcome of meaningful pain improvement without side effects, compared to just 21.9% in the THC group. Adverse reactions occurred in 15.5% of CBD users versus 35.7% of THC users, with discontinuation rates favoring CBD by a similar margin. However, the broader CBD evidence picture remains patchy. Epilepsy is where CBD shows the most robust clinical proof—the FDA-approved Epidiolex product demonstrates sustained seizure reduction across 144 weeks. For other conditions like pain and sleep, the clinical gaps are wider than most consumers expect, with recent Cochrane reviews finding no clear evidence that CBD-dominant products achieve meaningful neuropathic pain relief.

On the question of THC and driving safety, the evidence is more reassuring than headline readers might assume. Research shows that THC impairs cognitive functions like attention and memory, with effects comparable to low blood alcohol concentrations depending on dose and usage frequency. When cannabis is inhaled, effects peak within the first hour and taper over two to three hours, though they can persist up to four to six hours. Oral consumption extends that window dramatically—effects can last eight to twelve hours because cannabinoids are absorbed and metabolized more slowly through the gut. The counterintuitive finding: regular cannabis users show no driving impairment after 48 hours or more of abstinence, and medicinal cannabis prescribed for insomnia causes no next-day impairment. Some research even suggests THC makes drivers more cautious, leaving larger gaps behind other vehicles—a behavioral response that may offset some cognitive effects, though it's not a substitute for actual unimpaired driving.

Congress is churning out cannabis reform bills at a steady pace despite federal prohibition remaining intact. Sixteen cannabis-related bills have been filed during the 2025-2026 session, with the MORE Act (Marijuana Opportunity Reinvestment and Expungement) leading the pack at 62 sponsors. The MORE Act would remove marijuana from the Controlled Substances Act entirely, establish automatic expungement for certain federal marijuana offenses, create a new federal excise tax, and direct revenue toward community reinvestment and small business programs. Other proposals include the STATES 2.0 Act, which would prohibit federal enforcement against state-legal cannabis operations and enable interstate commerce; the CLIMB Act, which would allow state-legal cannabis businesses to list on major stock exchanges like Nasdaq; and the Hemp Planting Predictability Act, a bipartisan measure that would delay new hemp restrictions until November 2029. 💰 MONEY MOVES The broader landscape reveals how financial and regulatory frameworks are catching up with state-level legalization—exchanges, banking access, tax treatment, and insurance coverage are all being repositioned in anticipation of federal rescheduling, even though Congress hasn't yet passed comprehensive reform.

The scientific picture on cannabinoid combinations remains unsettled. The so-called "entourage effect"—the theory that THC, CBD, terpenes, and other compounds work better together than in isolation—has partial clinical support but is not yet settled science. Some evidence supports it: Sativex, a near-1:1 THC:CBD spray, showed superior pain relief compared to THC-only extracts in cancer patients, and epilepsy research found that 71% of patients improved on whole-plant CBD extracts versus 46% on purified CBD isolate. Yet several well-designed studies have produced contradictory findings, and the dose-response relationship for many cannabinoid combinations may follow an inverted-U curve, meaning more isn't always better. The gap between consumer adoption and clinical proof remains wide across the board—one in five American adults uses CBD, yet the FDA has approved only one CBD product for clinical use (Epidiolex for epilepsy). Until larger randomized controlled trials clarify which combinations work for which conditions at which doses, patients and providers are working with incomplete information, and that uncertainty is exactly what regulators like CMS are banking on as they move forward with coverage decisions based more on political momentum than definitive clinical evidence.

March 30, 2026

Texas bans smokable hemp products effective March 31, marking one of the most significant regulatory shifts for the state's hemp industry since legalization. The Texas Department of State Health Services adopted new rules that prohibit the sale and manufacture of smokable hemp items, including THCA flower and prerolled hemp cigarettes, with enforcement beginning at midnight tonight. Central to the change is the state's shift to a "total THC" standard, which includes THCA when calculating delta-9 THC levels—meaning products previously considered legal hemp will no longer meet the threshold and must be removed from shelves immediately.

💰 MONEY MOVES The financial impact on small businesses is staggering. Retailers face a licensing fee increase from $150 to $5,000 annually per location, while manufacturers jump from $250 to $10,000 yearly per facility. Todd Harris, co-owner of The Happy Cactus in Austin and chair of the retail committee for the Texas Hemp Business Council, said the banned products represent about 70% of his store's sales. At Emerald City Dispensary & Lounge in Fort Worth, owner Candice Stinnett reported similar losses: "The elimination of THCA products is about 60% to 70% of our business." Mark Bordas, executive director of the Texas Hemp Business Council, warned that "you're going to be wiping out access to a lot of product in a very short period of time," with some businesses already conducting fire sales over the weekend to clear inventory before the ban takes effect. At least one North Texas business is expected to close entirely as a result.

Meanwhile, Texas lawmakers are preparing for broader cannabis and psychedelic policy discussions. House Speaker Dustin Burrows directed his chamber's Public Health Committee to monitor the implementation of legislation enacted last year supporting clinical trials for ibogaine, a psychedelic currently being developed as a prescription medicine to treat substance use disorders and other mental health conditions. 🚀 THIS IS COOL This positions Texas as a leader in psychedelic-assisted medicine research, a field gaining momentum as FDA-backed trials demonstrate therapeutic potential for PTSD, depression, and addiction—areas where traditional pharmaceutical interventions have shown limited effectiveness for many patients.

The regulatory landscape reflects a state in transition. While Lt. Gov. Patrick studies the alleged harms of THC products to build a case for stricter bans, the state simultaneously invests in psychedelic medicine research, acknowledging that unconventional compounds can treat conditions traditional medicine struggles with. 🤔 THINK ABOUT IT If Texas recognizes ibogaine's therapeutic value enough to fund FDA clinical trials, why does the state ban smokable hemp products that veterans, chronic pain patients, and anxiety sufferers rely on—products with zero overdose deaths—while maintaining full legality for alcohol, which kills tens of thousands annually?